Antibody

1,032개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,032 programs
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Avelumab (TAK-981 + Avelumab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

TAS-102+bevacizumab+local treatment (TAS-102+bevacizumab+local treatment)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterApproved

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

Crohn Disease; Infliximab · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#Infliximab+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, TJ033721, TJ033721 (givastomig) , nivolumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleI-Mab Biopharma US LimitedPhase 1

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleAbbVieApproved

infliximab, adalimumab, etanercept (TNF blockers, TNF blockers (infliximab, adalimumab, etanercept))

Arthritis, Rheumatoid; Spondylitis, Ankylosing · Arthritis, Rheumatoid

#ArthritisRheumatoid#Antibody#Approved#monoclonal-antibody#Arthritis+3
Trials 1Status Active
AntibodyLimited DatastaleUniversity of CalgaryApproved

adalimumab (Humira, TNFa Antagonist - Adalimumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of CalgaryApproved

TNFa Antagonist - Infliximab (TNFa Antagonist - Infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

JS001 (TORIPALIMAB INJECTION, TORIPALIMAB INJECTION(JS001 ))

Biliary Tract Cancer (BTC) · Biliary Tract Cancer (BTC)

#BiliaryTractCancerBTC#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleDaping Hospital and the Researc…Phase 2

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

LA HNSCC · LA HNSCC

#LAHNSCC#Antibody#Phase2#monoclonal-antibody#Daping
Trials 1Status Recruiting
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

TPF, radiotherapy and cetuximab (TPF, radiotherapy and cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleChia Tai Tianqing Pharmaceutica…Phase 2

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

RAS/BRAF Wild Type Colorectal Cancer · RAS/BRAF Wild Type Colorectal Cancer

#RASBRAFWildTypeColorectalCancer#Antibody#Phase2#monoclonal-antibody#RAS+2
Trials 1Status Recruiting
AntibodyLimited DatastaleLeap Therapeutics, Inc.Phase 1

nivolumab (Opdivo, TRX518 with nivolumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Leap
Trials 1Status Active
AntibodyLimited DatastaleLeap Therapeutics, Inc.Phase 1

pembrolizumab (Keytruda, TRX518 with pembrolizumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Leap
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting

43 / 52 pages

← PreviousNext →